Jazz Pharmaceuticals Director Surrenders Shares for Tax Obligations

Insider Filing Analysis: Jazz Pharmaceuticals plc (NASDAQ: JAZZ)

Overview

On September 2, 2026, Jazz Pharmaceuticals plc filed a Form 4 report on behalf of Director Jennifer E. Cook, detailing transactions executed on August 31, 2026.

Key Transaction Details

• Security: Ordinary Shares
• Transaction Code: F (Payment of exercise price or tax liability by delivering or withholding securities)
• Number of Shares: 1,706 ordinary shares disposed of across two tranches (14 shares at $244.0643 and 1,692 shares at $241.39).
• Total Transaction Value: $411,848.78
• Post-Transaction Beneficial Ownership: 10,736 directly held ordinary shares.

Analysis & Context

• Nature of Transaction: Footnote (1) confirms these shares were withheld or sold strictly to satisfy tax withholding liabilities arising from the vesting of previously awarded restricted stock units (RSUs).
• Significance: Low. The disposition represents standard non-discretionary administrative share withholding rather than an open-market insider sale driven by market sentiment.